Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret A.s. · BIST:GENIL
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret A.s — Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. — Q3 2025 Earnings Presentation
36 slides from Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret A.s's earnings presentation, December 2025
Slide 1: For Healthier GENerations
KULA 2025 For Healthier GENerations
Slide 2: Brand
KULA Brand For Healthier GENerations
Slide 3: A View to GEN
KULA A View to 600+ 10 countries different 4 Affiliated Companies employees 22 global partner 7 Subsidiaries 7different countries 10 countries different 9 offices 13partner business abroad Turkish Medicine Industry Fastest Growing 15 Imported products Company (Since 2014) 7 different sales country 2
Slide 4: Business
KULA Business NPP Drugs Registered Imported Branded Generic Drugs which prescribed by the doctors Drugs Drugs for the treatment of diseases and In addition to original drugs, it Registered imported drugs refer to has activities on development import permission is given by the the product portfolio f
Slide 5: Strong Sales
KULA Strong Sales Q3 Sales by Years (TL / ‘000) The highest sales volume of all-times in the first nine months of 2025 TL 13 Bn 5.128 3.615 The highest sales volume of all-times 2.304 in the 2025/Q3 TL 5,1 Bn 432 1.296 21/Q3 22/Q3 23/Q3 24/Q3 25/Q3 Compare to the 2025/9M with 2024/9M 2024 – 2025 Fir
Slide 6: Drug
KULA Drug Comparing of NPP Drug sales for the 9- 35% Faaliyet Alanları 22/Q1 22/Q2 22/Q3 22/Q4 23/Q1 23/Q2 23/Q3 23/Q4 24/Q1 24/Q2 24/Q3 24/Q4 25/Q1 25/Q2 25/Q3 month period of 2025 versus the same period in 2024 increase Exported Drugs 57 81 80 26 96 60 45 120 209 127 92 182 291 226 184 Comparing t
Slide 7: Drug Sales
KULA Drug Sales The highest box sales of all time in the 9 Months Sales by Years (Boxes) first nine months of 2025 4.253.793 4.253.793 3.258.843 Compared to the same period of 3.005.540 2.774.961 2.507.344 2024, total box sales in the first nine months of 2025 %31 increase 2021 2022 2023 2024 2025 C
Slide 8: Export
KULA Export* Compared to the same period of 2024 in Export volume Export by Country in the first nine months of 2025 Country TL Azerbaijan 413.997.445 %64 increase Kazakhstan 183.321.433 Uzbekistan 17.071.961 Compared to the same period in 2024 Russia 79.059.432 in the 3rd quarter of 2025 Others** 7
Slide 9: Profitability
KULA Profitability Profitability In 2025/9M 657,6 mn TL Net Profit In 2025/9M with compared to the 2024/9M 385% increase In Operating Profit with compared to the 2024/9A TL 213 mn increase In Operating Profit with compared to the 2024/9M TL60 mn increase For Healthier GENerations
Slide 10: Income Statement
KULA Income Statement TL 30.09.2025 13.040.049.552 Net Sales 13.040.049.552 Gross Profit 2.919.337.204 Operating Profit 1.342.786.923 2.919.337.204 1.342.786.923 1.328.086.736 Net Profit 1.328.086.736 NET SALES GROSS PROFİT OPERATİNG PROFİT NET PROFİT * These are data in Turkish Lira for the period
Slide 11: Profit Margins
KULA Profit Margins In Consolidated Gross Profit in 2025/Q3 Profit Margins 1,03 mr TL 2024/Q3 2025/Q3 1.035.851.954 Compared to the Q3 of 2024 in 983.758.188 Gross Profit TL 52,1 mn increase 531.577.764 471.349.173 Compared to the Q3 of 2024 in Net Profit 213.379.338 47% increase 145.171.463 Compare
Slide 12: Profit Margins
KULA Profit Margins In Net Profit Margin Profit Margins 3,6 base point increase PROFIT MARGINS 30.09.2024 30.09.2025 In Operating Profit Margin 20,48% 19,60% 1,57 base point increase 11,47% 10,87% 10,54% 8,97% In Gross Profit Margin 4,58% 0,9 base point increase 0,93% GROSS PROFİT OPERATİNG EBITDA M
Slide 13: Balance Sheet
KULA Balance Sheet Equities Balance Sheet TL 9,7 Bn Current Ratio Assets & Liabilities 30.09.2025 31.12.2024 1,35 Total Current Assets 8.566.827.249 7.269.587.770 Total Fixed Assets 8.714.824.266 8.299.806.642 Assets Total Assets 17.281.651.515 15.569.394.412 17+ Bn TL Total Short Term Liabilities 6
Slide 14: 2025 Gerçekleşme
KULA 2025 Gerçekleşme 2025-9 Target Coverage Rate Sales 14.358.528.399 18.500.000.000 77,61% Gross Profit 2.940.397.615 3.750.000.000 78,41% Operating Profit 1.513.926.582 1.800.000.000 84,11% EBITDA 1.587.345.524 1.900.000.000 82,17% Gross Profit Margin 20,48% 20,27% Operating Profit Margin 10,54%
Slide 15: Growing
KULA Growing Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (GEN) and Santhera Pharmaceuticals, based in Switzerland, have signed an exclusive distribution agreement. Under the agreement, GEN will be the exclusive distributor in Türkiye for AGAMREE® (vamorolone), a product used in the treatment
Slide 16: Azerbaijan
KULA Azerbaijan First Local Drug Producer of Azerbaijan USD 900 mn drug market 66% GEN Shareholder USD 35 mn Investment 2 years project term 30% equity financing Incentives provided by Azerbaijan State For Healthier GENerations
Slide 17: Research and Development
KULA Research and Development TL 131,9 mn 34 14 R&D Investments in Continuing Number of new projects 2025/9M R&D Project planned for commercialization facility under construction in Azerbaijan 2 40+ Accredited Technology R&D Team R&D Center Focused Industrial Move Projects For Healthier GENerations
Slide 18: Drug
KULA Drug 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025* Toplam Number of In the first 9 months of 2025, Produced Drugs 8 1 18 2 9 17 30 24 18 16 5 148 Registered In Türkiye 6 1 7 0 2 1 4 6 0 3 3 33 Products 14 products were licensed in 2015-2025* Abroad 2 0 11 2 7 16 26 18 18 13 2 115 Türk
Slide 19: Rare Solutions For
KULA Rare Solutions For Solutions for Rare Drug Research for Alzheimer and other Diseases Like SMA, MS NSCLC and other neurodegenerative cancer types illnesses With the partnerships made GEN ease access of patients Collaboration maintains with Development of a new to drugs for rare diseases the RS R
Slide 20: Strong Subsidiaries
KULA Strong GENJECT ELIXIR Sağlık Ürünleri Kimya Sanayi Ticaret A.Ş. İlaç Araştırma ve Geliştirme A.Ş. Genject, its own brand in Türkiye, manufactures single-use GEN's shareholding rate in Elixir, which is hypodermic syringes in accordance with CE standards. integrated into the GEN Production Campus
Slide 21: Innovative Investments in
KULA Innovative Investments in For Healthier GENerations
Slide 22: Subsidiaries
KULA ACTIVITY AND SHARE SUBSIDIARIES ESTABLISHMENT MAIN ACTIVITY RATIO (%) PLACE USA Medical Device Development 19,30 Drug Research and Türkiye 11,70 Development Drug and Food Supplement Switzerland 4,55 Research and Development Biotechnological Medical Türkiye Device Research and 35,15 Development
Slide 23: Business Partners
KULA Business Partners For Healthier GENerations
Slide 24: Business Partners
KULA Business Partners For Healthier GENerations
Slide 25: Capacity
KULA Capacity STERILE NON-STERILE Liquid Injecton Vial Tablet and Film Coated Tablets 26.520.000 vials/year 400.000.000 tablets/year Lyophilized Injection Vial Hard Gelatin Capsule 5.300.000 vials/year 40.800.000 capsules/year Cartridges Sachet 10.200.000 cartridges/year 14.688.000 sachets/year Read
Slide 26: Solar Power Plant Investment
KULA USD 7 - 8 mn Solar Power Plant Investment 4,85 Mw Installed Solar Power 11,85 Mw installed capacity of the Solar Power Plant investment in Yozgat province %56 Female Manager Rate We Are Not Different, We Are Aware - Employment of Individuals with Autism %46 Female Employee Rate GEN is signatory
Slide 27: Production
KULA Production 43.000 m2 Closed Area TR GMP Türkiye, Azerbaijan, Moldova and Georgia FDA ANDA USA EMA EU GMP Europe EAEU GMP Russia, Kazakhstan Phippines FDA Philippines 1.200 m2 R&D Laboratory Republic of Türkiye Minister of Science, Industry and Technology R&D Center Accreditation For Healthier G
Slide 28: Stock
KULA Stock 30.09.2024 Price TL 89,69 30.09.2025 Price TL 184,90 30.09.2025 Market Size TL TL 55,47 Bn / USD 1,33 Bn GENIL XU 100 11.012,12 ₺184,90 9.665,78 ₺89,69 30.09.2024 30.09.2025 30.09.2024 30.09.2025 For Healthier GENerations
Slide 29: Innovative
KULA Innovative Project Name SUL-238 GN-037 RS-139 Indication Alzheimer's and Neurodegenerative diseases Psoriasis (Psoriasis Vulgaris) Solid Cancers Stage Phase 1 was completed Phase 2 completed. Phase 3 will be launched in 2026 Phase 1b is ongoing. The Probability of the Project Being Released, at
Slide 30: Indices
KULA NATIONAL INTERNATIONAL INDECS INDECS BIST STARS BIST ANKARA MSCI BIST PARTICIPATION 100 BIST 500 BIST PARTICIPATION 30 Small Cap BIST 100-30 BIST 100 BIST BUYBACK BIST DIVIDEND BIST SERVICES FTSE FTSE BIST PARTICIPATION BIST W. AND RETAIL DIVIDEND TRADE World Europe All-World BIST ALL SHARES BI
Slide 31: Summary
KULA Summary 30.09.2025 31.12.2024 30.09.2025 31.12.2024 ASSEST Short Term Liabilities Short Term Debts 1.583.866.535 497.351.361 Current Assets Short Term Portion of Long-Term Financial Debts 354.987.499 396.993.545 Cash and Cash Equivalents 416.732.998 681.049.855 Trade Payables Financial Assets 1
Slide 32: Equities
KULA Equities 30.09.2025 31.12.2024 EQUITIES Equity Attributable to Owners of the Parent Share Capital 300.000.000 300.000.000 Adjustment to Share Capital 2.013.207.104 2.013.207.104 Buyback Shares -89.333.026 -39.155.011 Share Premiums/Discounts 2.832.053.320 2.832.053.320 Other Comprehensive Incom
Slide 33: Summary
KULA Summary 1 Jan – 1 Jan – 1 July – 1 July – 30 Sept 25 30 Sept 24 30 Sept 25 30 Sept 24 Revenue 14.358.528.399 14.493.641.445 5.351.010.817 5.035.159.161 Cost of Sales (-) -11.418.130.784 -11.652.377.192 -4.315.158.863 -4.051.400.973 Gross Profit 2.940.397.615 2.841.264.253 1.035.851.954 983.758.
Slide 34: Investor Relations
KULA Investor Relations yatirimciiliskileri@genilac.com https://www.genilac.com.tr/yatirimci-iliskileri-gen For Healthier GENerations
Slide 35: Disclaimer
KULA All information presented in this presentation (presentation) has been prepared by Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (GENIL) in order to present information, projection and expressions about GENIL. The accuracy, adequacy and completeness of the information in this Presentation
Slide 36: Thank You.
KULA Thank You. For Healthier GENerations
Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. — Q3 2025 Earnings Presentation on 6ix